A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
This study is testing a new experimental medicine called SNV4818 for people with advanced cancers. Researchers want to find the safest and most effective dose of this medicine, either on its own or combined with other cancer treatments.
You might be able to join if you have advanced cancer with a specific genetic change called a PIK3CA mutation, and standard treatments have stopped working or were too hard to tolerate. Your vital organs must also be working well enough to safely handle the study treatments.
Participants will receive the study drug, potentially alongside other approved cancer medications like hormone or targeted therapy. The medical team will closely monitor your health, tumor size, and any side effects to see how well the treatment works.
This study is currently recruiting patients at locations in Los Angeles, Boston, and Philadelphia. Your care team will guide you through all the necessary visits and health checks.
- 1Testing a new cancer drug called SNV4818
- 2Looking for the safest and most effective dose
- 3Currently recruiting patients in select US cities
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.